Having undertaken, in 2006, the roll out of its initial sales force, in 2007 TSO3 started seeing the team’s efforts Take shape and new challenges appear.
Like a seed that was sown, TSO3 grew and is gradually spreading through the market.
This step was crucial: you only get one chance to make a good first impression. This is the only way to stand out, make your mark and take your rightful place.
Today, the early adopters are carrying a message that is invaluable for TSO3:
- Their total satisfaction with the utilization of the 125L Ozone Sterilizer;
- The major savings;
- The safe technology at the hub of their sterilization centre.
This group of innovators from nearly 30 healthcare facilities in North America are also the leaders of opinion, people committed to their professions, who rub shoulders with the members of numerous associations in the field. We are also active in these associations, where we are becoming better known and increasingly recognized.
In parallel, we must adjust to market demands and respond to new challenges. Recent months have allowed us to realize there is a growing need among the clientele for the sterilization of flexible endoscopic instruments, which were formerly rare and sterilized only with ethylene oxide. However, the very recent capacity of another sterilization method imposes on TSO3 an additional necessity from the clientele. We must therefore perfect the work necessary to guarantee the compatibility of this type of endoscope with our process – work that will require time and rigorousness, and slows our sales, but that is no different from the challenges we have already met in the past.
For more information:
Marc Boisjoli, Vice President Finance and Chief Financial Officer
(418) 651-0003, Ext. 228 / mboisjoli@tso3.com
Caroline Côté, Director, Corporate Communications and Investor Relations
(418) 651-0003, Ext. 237 / ccote@tso3.com